A Phase 4, Open-label Trial Describing the Safety, Tolerability, and Immunogenicity of the 13 Valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

Trial Profile

A Phase 4, Open-label Trial Describing the Safety, Tolerability, and Immunogenicity of the 13 Valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 May 2017

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 28 Nov 2016 Results of 1 and 2 years follow-up after vaccination published in the Pediatric Infectious Disease Journal.
    • 09 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top